While the epidermal growth factor receptor (EGFR) is an established regulator of skin development and homeostasis, the functions of the related tyrosine kinase receptors ERBB2 and ERBB3 in this tissue have only recently been examined. Previously reported, skin-specific deletion of each of these receptors in mice resulted in similar defects in keratinocyte proliferation and migration, resulting in impaired wound healing and tumorigenesis. Because both ERBB2 and ERBB3 are targets for treating an array of cancer types, it is important to examine the consequences of receptor inhibition in human keratinocytes. Here, we employed the CRISPR/Cas9 technology to generate HaCaT cells (an established human keratinocyte cell line) lacking ERBB2 or ERBB3. HaCaT clones lacking ERBB2 or ERBB3 showed comparable reductions in cell proliferation as assessed by BrdU staining. Apoptosis, in contrast, was reduced in ERBB3-deficient HaCaT cells only. Assessment of cell migration using a wound healing (scratch) assay showed that the closure of the wound gaps was completed by 48 h in mock and in ERBB3 knockout clones. In contrast, this process was considerably delayed in ERBB2 knockout clones, and a complete closure of the gap in the latter cells did not occur before 72 h. In conclusion, both ERBB2 and ERBB3 are essential for normal proliferation of skin keratinocytes, but in contrast to ERBB3, ERBB2 is essential for migration of human keratinocytes. These observations might bear significance to patient adverse effects of therapeutic agents targeting ERBB2 and ERBB3.
Introduction
Among the several growth factor receptors expressed in skin keratinocytes, the epidermal growth factor receptor (EGFR, ERBB1, HER1), a prototype tyrosine kinase receptor, occupies a prominent position. Several lines of evidence, including genetic deletion of the EGFR and deletion or overexpression of its ligands in laboratory mice, indicate that normal activity of this receptor is essential for epidermal and hair follicle development and homeostasis [1] [2] [3] [4] . Notably, anti-EGFR neutralizing antibodies (such as Cetuximab or Panitumumab) and small molecules (such as Erlotinib or Gefitinib) targeting the receptor, which are widely used for treating diverse cancer types, are known to cause a variety of skin toxicities, including rash, dryness, itching, as well as nail and hair abnormalities [5, 6] . These side effects corroborate the key homeostatic function of the EGFR in the skin.
ERBB2 (neu, HER2) and ERBB3 (HER3) are further members of the ERBB receptor family. Both receptors play an important role during mammalian development. Deletion of ERBB2 is lethal because of heart and neural defects during midgestation [7] . Mice lacking the ERBB3-receptor are not able to build Schwann cells and also die before birth [8] . ERBB2 is an orphan receptor without any known ligand [9] and ERBB3 has impaired kinase activity [10] . Notably, ERBB2/ERBB3 heterodimers show the strongest mitogenic activity of all ERBB receptor combinations, and their frequent presence in tumors makes them potential targets for a cancer therapy [11] . Monoclonal antibodies targeting ERBB2 (such as Trastuzumab) and ERBB3 (such as Patritumab, Seribantumab, and Lumretuzumab) are in development or have already been approved to treat different cancer types [12] . Several tyrosine kinase inhibitors, which very effectively block the receptor downstream signaling, are also available for ERBB2.
As both ERBB2 and ERBB3 are expressed in the skin and have potential functions in this tissue [1] , it is essential to assess possible side effects associated with their therapeutic intervention. For ERBB2, known side effects include cardiac dysfunction [13] and relatively mild skin effects [6] , while potential clinical side effects of ERBB3 repression remain unknown. In a first attempt to characterize the role of these receptors in the skin, we recently created and characterized mouse lines lacking ERBB2 [14] or ERBB3 [15] in skin keratinocytes. Our data revealed that loss of these receptors impaired keratinocyte proliferation/migration and affected key processes such as wound healing and tumorigenesis. To extend these observations to human keratinocytes, we employed the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system. Herein, we report the generation of ERBB2 and ERBB3 knockout clones of the human keratinocyte cell line HaCaT and the assessment of their signaling and functional properties.
Results

Generation of HaCaT cell clones lacking ERBB2 or ERBB3
To directly compare the roles of ERBB2 and ERBB3 in epidermal keratinocytes, we employed CRISPR/Cas9 technology to create clones of the human keratinocyte cell line HaCaT with targeted deletions of these receptors. As both ERBB2 and ERBB3 human genes encode several splice variants, we identified appropriate target sites for gene editing in an exon present in all reported variants: exon 6 for ERBB2 (Fig. 1A) and exon 2 for ERBB3 (Fig. 1B) . After transfection with Cas9, ERBB2-or ERBB3-gRNA, and surrogate plasmids [16] , cells were isolated using FACS (fluorescence-activated cell sorting), plated as individual clones in 96-well plates, and expanded. Amplification of the sequence flanking the target site by PCR and sequencing revealed that five out of six obtained ERBB2 clones and four out of five ERBB3 clones carried short deletions predicted to result in a frameshift mutation that would cause a truncated protein (data not shown). Table 1 provides an overview of the obtained results. Notably, attempts to obtain EGFR-targeted HaCaT clones using a similar strategy were not successful, in spite of the fact that a significantly higher number of transfected cells were screened (Table 1 and data not shown). This suggests that EGFR signaling is mandatory for HaCaT cell survival.
For further experiments, we chose clones 2/E2 and 2/F6 for ERBB2 (Fig. 1A) and clones 3/B8 and 3/F6 for ERBB3 (Fig. 1B) . Clone 2/E2 contained two different deletions in the two ERBB2 alleles, while mutations in all other clones were biallelic. As controls, we selected two mock-transfected clones (M/A1 and M/ B3). Western blotting revealed that while EGFR levels remained unchanged in all clones, ERBB2 or ERBB3 protein was completely absent in the corresponding clones, (Fig. 1C) . The western blot data were confirmed by FACS analysis: while the deleted ERBB receptor was not present on the cell surface, the other receptors were expressed at normal levels (Fig. 1D) . Thus, ERBB2 and ERBB3 knockout cell lines suitable for further studies were generated and validated.
Altered ERBB phosphorylation and signaling in ERBB2-or ERBB3-deficient keratinocytes
The ERBB receptor activation and phosphorylation of mitogen-activated protein kinase (MAPK) and RACalpha serine/threonine-protein kinase (AKT) after stimulation of the cell lines with epidermal growth factor (EGF, an EGFR ligand) or neuregulin-1-beta (NRG1, an ERBB3 ligand) differed significantly depending on the ablated receptor. Upon treatment with EGF, robust EGFR phosphorylation was maintained in ERBB2-and ERBB3-decificient cells, ERBB2 and ERBB3 phosphorylation were largely blocked in both clones ( Fig. 2A) , and AKT phosphorylation was impaired in ERBB2-deficient cells only (Fig. 2C) . Interestingly, phosphorylation of ERBB3 was still observed in ERBB2-deficient cells after NRG1 stimulation (Fig. 2B ), but the ability of NRG1 to increase the phosphorylation of MAPK and AKT was reduced in ERBB2-deficient cells and almost completely ablated in ERBB3-deficient cells (Fig. 2D) . In summary, ERBB2-and ERBB3-deficient cells largely displayed the signaling properties one would anticipate, further demonstrating their usefulness for functional studies.
Loss of ERBB2 or ERBB3 affects basal and ligandinduced proliferation, apoptosis, and migration
To quantify cell proliferation, we measured bromodeoxyuridine (BrdU) incorporation using a colorimetric immunoassay. As shown in 
3341
The FEBS Journal 284 (2017) 3339-3349 ª 2017 Federation of European Biochemical Societies ERBB2 or ERBB3 showed less proliferation compared to the mock clones under basal conditions. Treatment with EGF or NRG1 for 24 h was significantly less effective in ERBB2 and in ERBB3 knockout clones (Fig. 3A) . EGF stimulation was less effective in ERBB2 knockout clones than in ERBB3 knockout clones, while the opposite situation was observed with NRG1. Assessment of apoptosis with an annexin-based colorimetric assay revealed a significantly lower number of apoptotic cells in ERBB3-deficient cells, while the number of live, necrotic, or dead cells was not altered in ERBB2-or ERBB3-targeted clones compared to control cells (Fig. 3B ). Western blot analysis confirmed the results of the annexin A5 (ANXA5)-based apoptotic colorimetric assay (Fig. 4) . However, while ANXA5 expression is reduced in ERBB3 knockout cells, other pro-apoptotic proteins as caspase3 and its main target poly (ADPribose) polymerase (PARP) are not cleaved into their active version in an increased way. Also other proteins as mitogen-activated protein kinase 14 (MAPK14) and MAPK8, which are usually activated during cellular stress, are not altered in their phosphorylation state (Fig. 4) . Finally, we analyzed several proteins of the mitochondrial apoptotic pathway by western blot, but the expression of all investigated proteins was unchanged in ERBB-deleted cells compared to control cells (Fig. 5) .
Next, we analyzed cell migration in a wound healing assay. While closure of the wound gaps was completed by 48 h in mock clones and in ERBB3 knockout clones, this process was considerably delayed in ERBB2 knockout clones, and complete closure of the gap did not occur before 72 h (Fig. 6) . These results indicate that migration is affected by the absence of ERBB2, but not by the absence of ERBB3 in HaCaT cells.
ERBB2 and ERRB3 seem to play a negligible role in contact-induced regulation of proliferation
As an interaction between the EGFR and other proteins such as the cell adhesion molecule E-cadherin (CDH1) or the tumor suppressor Merlin (NF2, neurofibromin 2) is known to regulate contact inhibition of proliferation (see Discussion), we assessed how differences in confluence would alter expression of proteins potentially involved in this process. As expected, high confluence reduced both the total and the phosphorylated levels of EGFR (Fig. 7) . While ERBB2 levels were not affected by confluence at all, high confluence seemed to increase ERBB3 phosphorylation in ERBB2-deficient cells and total ERBB3 levels in both control and ERBB2-deficient cells (Fig. 7) . Finally, while E-cadherin levels decreased in all clones upon confluence, regardless of their ERBB status, no changes were observed in the expression of Merlin (Fig. 7) .
Discussion
Here, using CRISPR/Cas9-assisted gene disruption, we created ERBB2 and ERBB3 knockout clones of the human keratinocyte cell line HaCaT. After confirming loss of the corresponding protein and, accordingly, altered signaling upon treatment with EGF or NRG1, we functionally assessed the consequences for cell proliferation, apoptosis, and migration. As mouse lines lacking ERBB2 [14] or ERBB3 [15] specifically in the epithelial compartment of the skin have recently been characterized, we discuss below our findings in light of the mouse phenotype.
HaCaT clones lacking ERBB2 or ERBB3 showed, to a similar extent, a significant reduction in cell proliferation as assessed by BrdU staining. Interestingly, EGF stimulation was less effective in cells lacking ERBB2 compared to those lacking ERBB3, while NRG1 showed the inverse effect. This finding suggests, in contrast to previous studies [9] , that ERBB3 may represent a more important EGFR dimerization partner than ERBB2 -at least in HaCaT cells. While steady-state keratinocyte proliferation was unchanged in mice lacking ERBB2 [14] or ERBB3 [15] in the skin, both mouse lines showed impaired keratinocyte proliferation in skin wounds, in chemically induced skin tumors, and after induction of keratinocyte hyperproliferation. Apoptosis, which was reduced in ERBB3-deficient HaCaT clones, remained unchanged in the skin of ERBB2-and ERBB3-deficient mice. However, we found no evidence that other proteins of the classical apoptotic/stress pathway and of the mitochondrial apoptotic signaling pathway are altered in ERBB knockout cell lines.
Assessment of migration via a wound healing (scratch) assay showed that the closure of wound gaps by HaCaT cells was completed by 48 h in mock clones and in ERBB3 knockout clones. In contrast, this process was considerably delayed in ERBB2 knockout clones, such that a complete closure of the gap did not occur before 72 h. These results indicate that ERBB2 plays an essential role in migration of cultured human keratinocytes. Cell migration in general is an essential process in both physiological and pathological processes that involves a multitude of proteins and pathways, including cadherins for cell-cell adhesion, integrins for interactions with the extracellular matrix (ECM), release of matrix metalloproteases for ECM remodeling, and cytoskeletal rearrangements, among others [17] . The Rho family of GTPases is a key regulator of actin cytoskeleton dynamics in the context of cell migration [18] , and it has been shown that the stimulatory effect of nitric oxide on the migration of HaCaT cells seems to be mediated by the Rho GTPase signaling pathway [19] . Thus, it would be interesting Whatever the exact mechanism underlying the impaired migration upon loss of ERBB2 may be, our observation is consistent with observations in vivo: while skin wound healing was impaired in both ERBB3 del and ERBB2 del mice, the defect was much more pronounced in the case of ERBB2 deficiency. Notably, primary keratinocytes isolated from newborn ERBB2 del mice showed impaired ability to close the gaps of a scratch assay at both 48 h and 72 h [14] . These data, together with the delayed in vitro wound closure in ERBB2-deficient HaCaT clones, strongly indicate a cell autonomous role of this co-receptor in wound healing.
An interaction between EGFR and E-cadherin has been repeatedly implicated in the regulation of the socalled contact-dependent growth inhibition [20, 21] . Although it has been reported almost 20 years ago that ERBB2 can inhibit the transcription of the E-cadherin gene [22] , functional interactions between E-cadherin and ERBB2 or ERBB3 remained largely unexplored. To assess how differences in cell contacts would alter the expression of the potentially involved proteins, we examined control and ERBB2-or ERBB3-deficient cells at 50% or 100% of confluence. While EGFR and E-cadherin behaved as expected upon increasing confluence, no noteworthy alteration was observed regarding ERBB2 or ERBB3. We also did not observe any influence of the ERBB2 or ERBB3 status on the levels of Merlin, another protein known to affect EGFR [23] as well as ERBB2 and ERBB3 [24] in the context of contact-dependent inhibition of proliferation.
In summary, while mice lacking ERBB2 or ERBB3 specifically in the skin showed a largely comparable phenotype, our study using HaCaT clones with targeted mutations in ERBB2 or ERBB3 allows a more detailed analysis of specific and overlapping roles of these receptors in keratinocytes. Thus, ERBB2 seems to be more critical for skin wound healing compared to ERBB3. This observation may indicate that inhibition of ERBB2 within a therapeutic context may be associated with more cutaneous side effects compared to ERBB3. As our findings in HaCaT cells to a great extent confirm the functions of these receptors in keratinocytes derived from in vivo studies, we anticipate that genetic deletion of specific genes in cultured cell lines via CRISPR technology represents a good alternative to in vivo experiments. Apoptosis was assessed 48 h after starvation. Data were analyzed with Student's t-test and error bars represent SD (n = 4/group). Asterisks demonstrate significant differences related to the mock cell lines and rhombs show significant differences between both knockout cell lines. **P < 0.01, ***P < 0.001, # P < 0.05.
Materials and methods
Cell culture and CRISPR/Cas9-mediated gene editing
HaCaT cells were obtained from CLS Cell Lines Service (CLS, Eppelheim, Germany) and cultured in DMEM (FG 0435) (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (FCS) (Biochrom) and 1% streptomycin/penicillin (Biochrom) in an incubator (Thermo Fisher Scientific, Munich, Germany) at 37°C with 5% CO 2 .
For CRISPR/Cas-assisted gene, disruption cells were transfected with the following plasmids: Cas9-plasmid [25] , surrogate-plasmid [16] , and gRNA-plasmid [16] . For transfection, we used Lipofectamine 3000 (Invitrogen, Darmstadt, Germany) by following the instruction of the manufacturer. Forty-eight hours post transfection, cells were dissociated, resuspended in DMEM medium and then analyzed and sorted with a FACS Aria II (Becton Dickinson, Heidelberg, Germany). Enrichment of cells with RGEN activity was accomplished by single-cell sorting GFP and mCherry positive cells into 96-well plates (Falcon, Kaiserslautern, Germany) containing 150 ll DMEM medium. Following gRNA sequences were used to disrupt the gene sequence: EGFR-gRNA:
To analyze the CRISPR/Cas mutation, the region of the gRNA-binding side was amplified by PCR using the following primers: hEGFR_s: Frankfurt, Germany) and 10 different clones were sequenced to detect the mutation side. Identified knockouts were confirmed by western blot analysis.
Western blots
Protein was extracted using Laemmli-extraction-buffer, the concentration was estimated via bicinchoninic acid assay and 20 lg of total protein was separated by 8% or 12% SDS/PAGE and transferred to PVDF membranes (Millipore, Schwalbach, Germany) by semidry blotting. Membranes were blocked in 5% w/v fat-free milk powder (Roth, Karlsruhe, Germany) for 1 h at room temperature. After washing in Tris-buffered saline solution with 0.1% Tween 20 (Sigma, Taufkirchen, Germany), membranes were incubated over night at 4°C in 5% w/v BSA (Sigma) with the appropriate primary antibody. All antibodies and their dilution are shown in Table 2 . Membranes were washed and incubated in 5% w/v fat-free milk powder with a horseradish peroxidase-labeled secondary antibody. Signals were detected using an enhanced chemiluminescence detection reagent (GE Healthcare, Munich, Germany) and appropriate x-ray films (GE Healthcare). After detection, membranes were stripped by incubation with an appropriate buffer (2% SDS, 62.5 mM Tris/HCl, pH 6.7 and 100 mM bmercaptoethanol) for 40 min at 70°C and incubated with a second primary antibody recognizing the total protein of a phosphorylated protein or a housekeeper protein. 
